SHOULD A TEST DOSE OF LIDOCAINE WITH EPINEPHRINE BE USED WITH THE "WALKING EPIDURAL" TECHNIQUE?

1998 ◽  
Vol 86 (Supplement) ◽  
pp. 385S ◽  
Author(s):  
&NA; Roccaforte ◽  
L Susser ◽  
J Lax ◽  
J Weinberg ◽  
E Fernandez ◽  
...  
Keyword(s):  
Pharmaceutics ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 297
Author(s):  
Mohammed H. Elkomy

This study investigates the pharmacokinetic (PK) and pharmacodynamic (PD) consequences of shifting from Quetiapine fumarate immediate-release (IR) to extended-release (XR) formulation in non-adherent schizophrenia patients. Monte-Carlo simulations using population PK and PD models were implemented to predict the time course of plasma concentration and Brief Psychiatric Rating Scale (BPRS) scores following the oral administration of 200 mg Seroquel® every 12 h and 400 mg Seroquel XR® every 24 h in patients experiencing dose delay, omission or doubling. Parameters were computed and their distributions were compared using the Kolmogorov–Smirnov test. Dose irregularities with both formulations had different effects on plasma concentration and %reduction in BPRS scores from baseline. However, the odds ratio of getting a %reduction in BPRS below 14%, or plasma concentration exceeding 500 µg/L, were comparable for adherent and non-adherent patients. Plasma therapeutic concentration after treatment cessation was maintained for <24 h in 48% and 29.6% of patients, and a steady state recovery time of <48 h was achieved in 51% and 13.4% of patients on the IR and XR formulations, respectively. Monte-Carlo simulations predict that the risks associated with the IR dose irregularities are not worsened when the XR formulation is used instead. Non-adherence events involving a single dose of either formulation do not require rescue doses.


1980 ◽  
Vol 59 (10) ◽  
pp. 811 ◽  
Author(s):  
Robert Hodgkinson ◽  
Farkhanda J. Husain
Keyword(s):  

1994 ◽  
Vol 79 (1) ◽  
pp. 194
Author(s):  
Sheng K. Lin
Keyword(s):  

1999 ◽  
Vol 24 (Supplement 1) ◽  
pp. 74 ◽  
Author(s):  
Manuel Vallejo ◽  
G. Mandell ◽  
F. Jaime ◽  
S. Ramanathan

2015 ◽  
Vol 74 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Louise A. Fischer ◽  
Jeanne D. Johansen ◽  
Aage Voelund ◽  
Carola Lidén ◽  
Anneli Julander ◽  
...  

1989 ◽  
Vol 71 (Supplement) ◽  
pp. A852 ◽  
Author(s):  
P Youngstrom ◽  
M Hoyt ◽  
J C Veille ◽  
I Cohen ◽  
S Amini ◽  
...  
Keyword(s):  

PEDIATRICS ◽  
1948 ◽  
Vol 1 (4) ◽  
pp. 505-511
Author(s):  
STEWART H. CLIFFORD ◽  
KATHLEEN FAHEY WELLER

Forty-two premature infants were tested for vitamin A absorption after the oral ingestion of 0.5 cc. (35,000 U.S.P. units) of percomorph liver oil. Only three (7%) showed good absorption levels. The mean absorption level found from three to five hours after the test dose was 16 units of vitamin A. Forty-one were tested for vitamin A absorption after the oral ingestion of either 2 cc. or 3 cc. (16,000-24,000 U.S.P. units) of vitamin A in a vehicle of either alcohol or propylene glycol. Of these 37 (90%) showed good absorption levels. The mean absorption level found from three to five hours after the test dose was 85 units of vitamin A. Retrolental fibroplasia could not be prevented from developing in a certain number of premature infants' eyes by the daily oral administration of 5000 U.S.P. of vitamin A in an absorbable water soluble form. Even the addition of 20,000 U.S.P. units of vitamin A in oil by intramuscular injection failed to prevent the development of bilateral retrolental fibroplasia in one infant. If vitamin D follows the same laws of absorption as does vitamin A, the provision of both A and D in a readily absorbable form should be of great practical advantage to the prematurely born infant.


Sign in / Sign up

Export Citation Format

Share Document